DALLAS, Aug. 5, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Spectrum Pharmaceuticals Inc. (SPPI). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.
The investment report on Spectrum Pharmaceuticals Inc. (Nasdaq:SPPI) should be of particular interest to other biopharmaceutical companies: Allergan Inc. (NYSE:AGN), Par Pharmaceutical Companies (NYSE:PRX), Bristol Myers Squibb Co. (NYSE:BMY) and Johnson & Johnson (NYSE:JNJ).
It is available at: http://www.stockpreacher.com/n/SPPI
Spectrum Pharmaceuticals Inc. (SPPI), a commercial-stage biotechnology company with a focus on oncology, develops and commercializes a portfolio of drug products. Its marketed products include ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma (NHL); and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma.
The Company is also developing apaziquone for the treatment of non-muscle invasive bladder cancer. Its phase II products include Ozarelix, a drug being investigated for benign prostatic hypertrophy (BPH), a non-cancerous enlargement of the prostate, and hormone dependent prostate cancer; and Ortataxel, a third-generation taxane.
In the report, the analyst notes:
"SPPI operates in the most rapidly growing segment of treatment in the pharmaceutical market. Market research company RNCOS reported that the worldwide market for cancer treatment is anticipated to exceed $78 billion by 2012. With the increasing prevalence of this disease on top of the huge number of needs that are yet to be met in the field of cancer treatment, the report indicates the cancer therapy segment as a highly potential market.
"Moving forward with one of its near-term value drivers, SPPI, together with partner Allergen Inc. (AGN), announced the FDA has granted Fast Track Designation for the investigation of apaziquone, expediting the review of the drug. The Company looks forward to continuing with phase III studies evaluating the efficacy and safety of apaziquone."
To read the entire report visit: http://www.stockpreacher.com/n/SPPI
See what investors are saying about all these stocks at: http://www.stockhideout.com/
StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: http://www.stockpreacher.com
StockPreacher.com Disclosure
StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.